KRAS G12D-IN-29
KRAS G12D inhibitor 29 (Compound Formula (I) ) is an orally active and selective KRASG12D mutant inhibitor. KRAS G12D inhibitor 29 blocks downstream signaling pathways mediated by KRASG12D, suppressing tumor cell proliferation. KRAS G12D inhibitor 29 is promising for research of KRASG12D mutation-related cancers (such as pancreatic cancer, lung cancer, colorectal cancer) [1].
Product Specifications
CAS Number
3018057-89-8
UNSPSC
12352005
Target
Ras
Related Pathways
GPCR/G Protein; MAPK/ERK Pathway
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Purity
97.02
Solubility
DMSO : 125 mg/mL (ultrasonic)
Smiles
FC(F)(F)C1=C(C2=NC3=C4C(N(C[C@@H]5N[C@H]6CC5)[C@@H]6[C@H](C)O3)=NC(OC[C@]78N(C[C@H](F)C8)CCC7)=NC4=C2F)C=C(N)C(F)=C1C
Molecular Formula
C31H33F6N7O2
Molecular Weight
649.63
References & Citations
[1]Paroma CHAKRAVARTY, et al. Polymorphs of and synthetic process for an aza-tetracyclic oxazepine inhibitor of kras-g12d. WO2025111586A1. 2025-05-30.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
K-Ras
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
